Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Secretin Clear all
Terminated Phase 3 Interventional

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

NCT04231279
View directory record Official record
Conditions
Abdominal Pain, Irritable Bowel Syndrome
Interventions
synthetic human secretin
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
6 Months to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 20, 2026, 9:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cancer of the Pancreas Screening Study (CAPS 3)

NCT00438906
View directory record Official record
Conditions
Pancreatic Neoplasm, Peutz-Jeghers Syndrome
Interventions
Biopsy, Fine Needle Aspiration (FNA), Secretin (human synthetic) - ChiRhoClin
Procedure · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 20, 2026, 9:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Novel Breath Test to Detect Early Stage Chronic Pancreatitis

NCT01184573
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Not listed
Lead sponsor
Metabolic Solutions Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Secretin Infusion for Pain Due to Chronic Pancreatitis

NCT01265875
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Human Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 20, 2026, 9:54 AM EDT
Withdrawn Not applicable Interventional

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

NCT01094535
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 20, 2026, 9:54 AM EDT
Not listed Phase 2 Interventional

Secretin for Acute Pancreatitis

NCT03686618
View directory record Official record
Conditions
Pancreatitis, Acute
Interventions
Secretin
Drug
Lead sponsor
ChiRhoClin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection

NCT02160808
View directory record Official record
Conditions
Injury of Body of Pancreas
Interventions
Secretin, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

EUS Ductal Evaluation in One Endoscopic Session for the Diagnosis of Exocrine Pancreas Disease

NCT01997476
View directory record Official record
Conditions
Pancreatic Disease
Interventions
Combined EUS, e-PFT and sEUS Testing
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 20, 2026, 9:54 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects

NCT07285863
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Chronic Pancreatitis
Interventions
Secretin (human synthetic) - ChiRhoClin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 3 Interventional

Synthetic Human Secretin in Children With Autism

NCT00036244
View directory record Official record
Conditions
Autism
Interventions
RG1068 (Synthetic Human Secretin)
Drug
Lead sponsor
Repligen Corporation
Industry
Eligibility
32 Months to 59 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2005 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial of Indomethacin in Chronic Pancreatitis

NCT04207060
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Indomethacin, Placebo, Endoscopy for Pancreatic Function Testing
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 20, 2026, 9:54 AM EDT
Recruiting No phase listed Observational

Secretin in Refeeding

NCT05235867
View directory record Official record
Conditions
Anorexia in Adolescence
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 24 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Secretin in Functional Dyspepsia and Healthy Subjects

NCT03617861
View directory record Official record
Conditions
Dyspepsia, Healthy
Interventions
Human Secretin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Not applicable Interventional

Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?

NCT03263481
View directory record Official record
Conditions
Cholangiopancreatography, Endoscopic Retrograde
Interventions
Intraductal secretin test (IDST)
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Not applicable Interventional

Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis

NCT00651053
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
EUS
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 20, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional

Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

NCT00621556
View directory record Official record
Conditions
Intraductal Papillary Mucinous Neoplasms
Interventions
RG1068 (Synthetic Human Secretin)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder

NCT00216294
View directory record Official record
Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
RG1068 (Synthetic Human Secretin)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 20, 2026, 9:54 AM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Imaging Biomarkers of Pancreatic Function and Disease

NCT05659147
View directory record Official record
Conditions
Pancreatitis, Diabetes Mellitus
Interventions
Research MRI without administration of intravenous secretin, Research MRI with administration of intravenous secretin, Genetic Sequencing, Blood Tests, Stool Tests, Survey Completion, Endoscopic pancreatic function tests (ePFTs), Secretin
Diagnostic Test · Genetic · Other + 1 more
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 20, 2026, 9:54 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

NCT06276764
View directory record Official record
Conditions
IPMN, Pancreatic, Pancreas Cancer, Pancreatic Cyst
Interventions
LINFU®
Diagnostic Test
Lead sponsor
Adenocyte, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2034
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics

NCT02869893
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Secretin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 20, 2026, 9:54 AM EDT
Terminated Phase 1 Interventional

Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis

NCT00620919
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
RG1068 (Synthetic Human Secretin)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2009 · Synced Oct 20, 2026, 9:54 AM EDT
Withdrawn No phase listed Observational

Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis

NCT01845467
View directory record Official record
Conditions
Cellular Diagnosis, Pancreatic Cancer, Autoimmune Pancreatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
19 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 20, 2026, 9:54 AM EDT
Completed Phase 2 Interventional

Effects of RG1068 (Secretin) on Information Processing in Schizophrenia

NCT00235274
View directory record Official record
Conditions
Schizophrenia
Interventions
Subcutaneous Secretin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 20, 2026, 9:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

NCT00587132
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 20, 2026, 9:54 AM EDT